Mirtazapine Viatris (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and antagonizes postsynaptic 5‑HT2 and 5‑HT3 receptors, enhancing serotonergic neurotransmission. Its strong H1‑histamine antagonism contributes to sedation, while the combined actions raise overall monoamine activity linked to mood improvement.

The exact dose is individualized by the prescribing clinician based on the patient’s clinical status, age, and tolerability. Typical starting doses range from low to moderate, with adjustments made according to therapeutic response and side‑effect profile.

Safety data for mirtazapine in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs the possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature requirements), and necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from selective serotonin reuptake inhibitors (SSRIs) by its dual noradrenergic and serotonergic activity and strong antihistamine effect. This profile often results in greater sedation and appetite stimulation, which can be advantageous for patients with insomnia or weight loss, whereas SSRIs tend to have fewer sedative properties.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging to protect from moisture and light. Do not refrigerate or freeze the tablets, and ensure the container remains tightly closed throughout its shelf life.

Mirtazapine Viatris is taken orally, usually once daily in the evening due to its sedative effect. The tablet should be swallowed whole with water and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious adverse events include the potential for suicidal thoughts or behaviors, especially early in treatment, severe hypersensitivity reactions such as Stevens‑Johnson syndrome, agranulocytosis, seizures, and cardiac arrhythmias like QT prolongation. Prompt medical attention is required if any of these occur.

Mirtazapine is contraindicated in patients with known hypersensitivity to the drug, those currently taking monoamine oxidase inhibitors, or individuals with severe hepatic impairment. Caution is also advised for patients with a history of bipolar disorder, uncontrolled epilepsy, or significant cardiac conduction abnormalities.